Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $1,278,889.92 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 15,642 shares of the firm’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $81.76, for a total transaction of $1,278,889.92. Following the completion of the transaction, the executive vice president directly owned 32,105 shares in the company, valued at approximately $2,624,904.80. The trade was a 32.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Eric Swayze also recently made the following trade(s):

• On Friday, January 30th, Eric Swayze sold 6,179 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $82.93, for a total transaction of $512,424.47.
• On Friday, January 16th, Eric Swayze sold 49 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $75.97, for a total transaction of $3,722.53.
• On Friday, January 16th, Eric Swayze sold 9,884 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $75.34, for a total value of $744,660.56.
• On Friday, January 2nd, Eric Swayze sold 23,463 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $79.12, for a total value of $1,856,392.56.

Ionis Pharmaceuticals Stock Performance

NASDAQ:IONS opened at $80.60 on Monday. The company has a debt-to-equity ratio of 0.96, a quick ratio of 2.78 and a current ratio of 2.79. The stock has a 50-day simple moving average of $80.70 and a two-hundred day simple moving average of $69.49. The firm has a market capitalization of $13.05 billion, a PE ratio of -47.69 and a beta of 0.29. Ionis Pharmaceuticals, Inc. has a 52-week low of $23.95 and a 52-week high of $86.74.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Royal Bank Of Canada lifted their target price on shares of Ionis Pharmaceuticals from $82.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Bank of America raised their price target on Ionis Pharmaceuticals from $86.00 to $97.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Wall Street Zen lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Raymond James Financial reissued a “strong-buy” rating and set a $89.00 target price (up previously from $85.00) on shares of Ionis Pharmaceuticals in a research note on Thursday, October 30th. Finally, Wells Fargo & Company upped their price target on Ionis Pharmaceuticals from $82.00 to $100.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.95.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in IONS. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter valued at about $25,000. Golden State Wealth Management LLC lifted its stake in shares of Ionis Pharmaceuticals by 198.4% during the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after acquiring an additional 250 shares during the last quarter. Mather Group LLC. purchased a new stake in Ionis Pharmaceuticals in the third quarter worth $27,000. Brown Brothers Harriman & Co. bought a new stake in Ionis Pharmaceuticals during the 4th quarter valued at about $27,000. Finally, Allworth Financial LP grew its stake in Ionis Pharmaceuticals by 231.8% in the 2nd quarter. Allworth Financial LP now owns 740 shares of the company’s stock worth $29,000 after acquiring an additional 517 shares in the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.